TEVATEVA PHARMACEUTICAL INDUSTR...

NYSE tevapharm.com


$ 16.79 $ -0.12 (-0.71 %)    

Wednesday, 07-Aug-2024 15:59:51 EDT
QQQ $ 431.72 $ -4.76 (-1.08 %)
DIA $ 387.79 $ -2.19 (-0.56 %)
SPY $ 518.50 $ -3.49 (-0.67 %)
TLT $ 95.87 $ -0.68 (-0.7 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 16.79
$ 17.04
$ 16.78 x 800
$ 16.80 x 800
$ 16.60 - $ 17.04
$ 8.06 - $ 18.03
6,266,285
na
19.02B
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-12-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 02-10-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 07-27-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-09-2022 12-31-2021 10-K
12 10-27-2021 09-30-2021 10-Q
13 07-28-2021 06-30-2021 10-Q
14 04-28-2021 03-31-2021 10-Q
15 02-10-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-19-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 02-12-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-22

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

 tech-stocks-on-track-for-best-session-in-5-months-ahead-of-fed-meeting-small-caps-target-highest-close-since-january-2022-whats-driving-markets-wednesday

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...

 teva-beats-q2-estimates-raises-annual-outlook-on-strong-generic-austedo-sales

Teva Pharmaceutical reported Q2 2024 sales of $4.16 billion, surpassing the $4.06 billion consensus. Revenue rose 7% YoY, drive...

 wall-street-remains-on-track-for-amd-led-rebound-ahead-of-fed-decision-meta-earnings-analyst-says-the-bull-tends-to-remain-despite-near-term-volatility

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...

 teva-pharmaceutical-expects-2024-revenues-of-160b-164b-versus-prior-guidance-of-157b-163b-and-consensus-of-16012b

Outlook for 2024 Non-GAAP Results $ billions, except EPS or as noted July 2024 Outlook January 2024 Outlook ...

 apple-amazon-microsoft-meta-lead-the-charge-as-investors-bank-on-tech-cheer-for-rallys-reacceleration-week-ahead-in-earnings

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say followin...

Core News & Articles

Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment T...

 why-hims--hers-heath-shares-are-surging-today

Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appoi...

 tevas-migraine-treatment-found-effective-for-children-as-young-as-6

Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in chil...

 teva-space-pediatric-phase-3-study-met-its-primary-end-point-for-efficacy-with-a-significantly-greater-reduction-in-monthly-migraine-days-compared-to-placebo-efficacy-is-consistent-with-ajovy--pivotal-phase-3-and-real-world-evidence-studies-in-adults-with-no-new-emergent-safety-signals-observed

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine...

 jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there

Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run c...

Core News & Articles

- SEC Filing

 ubs-maintains-buy-on-teva-pharmaceutical-indus-raises-price-target-to-24

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $22 to...

 ftc-crackdown-on-teva-pharmaceuticals-over-inhaler-patent-abuse

The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain h...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION